GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)

GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)

Objective: To determine the efficacy and safety of intermittent docetaxel chemotherapy guided by circulating methylated glutathione S-transferase Pi-1 ( mGSTP1 ) in men with metastatic castration-resistant prostate cancer (CRPC). Patients and Methods: GUIDE (NCT04918810) is a randomised, two-arm, no...

Full description

Bibliographic Details
Main Authors: Ciara Conduit, Blossom Mak, Wenjia Qu, Juliana Di Lulio, Ronan Burder, Matthias Bressel, Thomas Cusick, Haryana M. Dhillon, Richard De Abreu Lourenço, Craig Underhill, Javier Torres, Megan Crumbaker, Florian Honeyball, Anthony Linton, Ray Allen, Ian D. Davis, Susan J. Clark, Lisa G. Horvath, Kate L. Mahon
Format: Article
Language:English
Published: SAGE Publishing 2022-04-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359221092486

Internet

https://doi.org/10.1177/17588359221092486

Similar Items